Winton Matthew
Known title: Chief Commercial and BusinessCIK: 0001971400
Winton Matthew's purchase track record
Winton Matthew has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2025 | CRVO | $117K | -38.5% | -55.2% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRVO | ▲ Buy | Open Market | 1,500 | $12K | 11/18/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 3,500 | $30K | 11/17/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 10,000 | $76K | 11/14/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CervoMed Reports PK Data and FDA Removal of Exposure Limit
CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.
CervoMed Reports PK Data and FDA Removal of Exposure Limit. CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.